[ORGANIZATION]
Meiji Yasuda Life Insurance Company
Featured in 2 tracked stories · first seen
Situations
Japanese biotechnology funding for cancer research
2 clusters · 4 sources · last updated
Latest: ANRis raises 220 million yen for KRAS mutation cancer drug development
Japanese biotechnology ventures are securing funding to advance nucleic acid-based cancer research and diagnostics. MiRNDa, Inc. completed a seed funding round led by Takanawa Gateway Global Benefit Investment Limited P
Also covered in
-
Cozre Inc. report reveals shifting trends in Japan's educational insurance market
[BUSINESS] · 2 sources ·